Drugs / PREOB®
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02061995 | Dec 2013 → Oct 2016 | osteoporosis | Erasme University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02890537 | Oct 2003 → May 2011 | avascular necrosis | Erasme University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01756326 | Jun 2012 → Apr 2018 | — | Bone Therapeutics S.A | Terminated | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01529008 | Nov 2011 → May 2017 | avascular necrosis | Bone Therapeutics S.A | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PREOB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02890537 ↗ |
| Modality | Cell therapy | “a proprietary population of autologous osteoblastic cells (PREOB®) has been developed.” NCT01529008 ↗ |
| Route | Other | “implantation of PREOB® into the necrotic lesion” NCT01529008 ↗ |